A detailed history of Simplex Trading, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 24,645 shares of CRDF stock, worth $68,020. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,645
Previous 37,591 34.44%
Holding current value
$68,020
Previous $200,000 73.0%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$2.22 - $5.89 $28,740 - $76,251
-12,946 Reduced 34.44%
24,645 $54,000
Q1 2024

Apr 25, 2024

BUY
$1.46 - $5.91 $54,882 - $222,162
37,591 New
37,591 $200,000
Q3 2023

Nov 01, 2023

BUY
$1.38 - $2.18 $21,460 - $33,901
15,551 New
15,551 $21,000
Q4 2022

Feb 02, 2023

SELL
$1.22 - $1.66 $14,158 - $19,264
-11,605 Reduced 52.5%
10,500 $14,000
Q3 2022

Nov 04, 2022

SELL
$1.54 - $3.21 $68,437 - $142,652
-44,440 Reduced 66.78%
22,105 $34,000
Q2 2022

Aug 03, 2022

BUY
$1.17 - $2.61 $46,844 - $104,499
40,038 Added 151.05%
66,545 $146,000
Q1 2022

May 02, 2022

SELL
$2.11 - $7.25 $70,957 - $243,810
-33,629 Reduced 55.92%
26,507 $65,000
Q4 2021

Feb 23, 2022

BUY
$5.18 - $7.24 $288,401 - $403,094
55,676 Added 1248.34%
60,136 $361,000
Q3 2021

Oct 28, 2021

SELL
$5.01 - $7.58 $1,733 - $2,622
-346 Reduced 7.2%
4,460 $29,000
Q2 2021

Aug 12, 2021

BUY
$6.65 - $10.04 $31,959 - $48,252
4,806 New
4,806 $31,000
Q1 2021

Apr 26, 2021

SELL
$9.1 - $19.57 $3,676 - $7,906
-404 Closed
0 $0
Q4 2020

Feb 02, 2021

BUY
$12.02 - $24.71 $4,856 - $9,982
404 New
404 $7,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $120M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.